Written agreement from FDA for single-arm, open-label, baseline-controlled registrational trial evaluating composite primary endpoint of improvement in CGI-I and gain of developmental milestone/skill ...
Only about one in five people with cancer enroll in clinical trials, and the largest barrier to participation may be far ...
The phase 3 OVATION 3 trial will evaluate IMNN-001's efficacy and safety in advanced ovarian cancer patients, comparing it with standard chemotherapy. Phase 2 results demonstrated a 35% improvement in ...
Innovations in clinical trial designs and tools have the potential to unlock a new era of research that is more convenient for patients, more reflective of real-world treatment conditions, and more ...
Pathkey has entered a master collaboration agreement (MCA) with Armstrong Clinical, a clinical development consultancy in Melbourne, Australia. This partnership aims to leverage Pathkey’s predictive ...
Oncology clinical trials drive some of the most important advances in medicine, yet they remain some of the most challenging to design and run. Intensive assessments, frequent amendments, complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results